LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway

J Orthop Surg Res. 2022 Dec 21;17(1):557. doi: 10.1186/s13018-022-03449-y.

Abstract

Background: Osteosarcoma is highly malignant. The migration, invasion, and chemoresistance contribute to poor prognosis of osteosarcoma. Research reported that endogenous bornavirus-like nucleoprotein 3 pseudogene (EBLN3P) promotes the progression of osteosarcoma.

Methods: In this study, the expression of EBLN3P in osteosarcoma tissue with different methotrexate (MTX) treatment responses was measured. Osteosarcoma cell lines with MTX resistance were constructed, and bioinformatic analysis was performed to explore the potential involved targets and pathways.

Results: Higher EBLN3P was associated with MTX resistance. Downregulation of LncEBLN3P decreased the MTX resistance of osteosarcoma cells by sponging miR-200a-3p, an important microRNA that affects epithelial-mesenchymal transition (EMT). The decreased miR-200a-3p resulted in the upregulation of its target gene O-GlcNAc transferase (OGT), which in turn promoted the EMT process of osteosarcoma cells. Further analysis confirmed that the loss of OGT and over-expression of miR-200a-3p could partly abolish the MTX resistance induced by LncEBLN3P.

Conclusion: LncEBLN3P is upregulated in osteosarcoma and increases the MTX resistance in osteosarcoma cells through downregulating miR-200a-3p, which in turn promoted the EMT process of osteosarcoma cells by increasing the OGT.

Keywords: LncRNA EBLN3P; Methotrexate; O-GlcNAc transferase; Osteosarcoma; miR-200a-3p.

MeSH terms

  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / genetics
  • Bone Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Movement / genetics
  • Cell Proliferation / genetics
  • Drug Resistance, Neoplasm* / genetics
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Methotrexate* / pharmacology
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / genetics
  • Osteosarcoma* / pathology
  • Pseudogenes
  • RNA, Long Noncoding* / genetics

Substances

  • Methotrexate
  • MicroRNAs
  • O-GlcNAc transferase
  • RNA, Long Noncoding
  • MIRN200 microRNA, human